sparfloxacin has been researched along with zithromax in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Cui, L; Hiramatsu, K; Neoh, HM; Shoji, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Citron, DM; Goldstein, EJ; Nesbit, CA | 1 |
| Bermudez, LE; Inderlied, CB; Young, LS | 1 |
| Courdil, M; Escaffre, MC; Lareng, MB; Lefèvre, JC | 1 |
| Anzalone, G; Ouadrhiri, Y; Scorneaux, B; Tulkens, PM | 1 |
| Andrews, JM; Boswell, F; Brenwald, NP; Wise, R | 1 |
| Cars, O; Löwdin, E; Odenholt, I | 1 |
| Ouadrhiri, Y; Scorneaux, B; Sibille, Y; Tulkens, PM | 1 |
| Goss, TF; Najib, MM; Stein, GE | 1 |
| Katouno, Y; Kobayashi, Y; Sugita, K; Uchida, H | 1 |
16 other study(ies) available for sparfloxacin and zithromax
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Chromosome Walking; DNA-Binding Proteins; Genetic Engineering; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Point Mutation; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Bites, Human; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Wound Infection | 1995 |
Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.
Topics: Anti-Infective Agents; Azithromycin; Bacterial Adhesion; Fluoroquinolones; Humans; Intestinal Mucosa; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolones; Rifabutin; Tumor Cells, Cultured | 1994 |
In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Chlamydia trachomatis; Clarithromycin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; In Vitro Techniques; Quinolones | 1993 |
Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cell Line; Fluoroquinolones; Humans; Interferon-gamma; Listeria monocytogenes; Macrophage Activation; Macrophages; Quinolones; Recombinant Proteins; Tetradecanoylphorbol Acetate; Virulence | 1996 |
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteroides fragilis; Chlamydia; Ciprofloxacin; Clarithromycin; Doxycycline; Enterobacter; Erythromycin; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Naphthyridines; Piperazines; Pseudomonas aeruginosa; Quinolones; Streptococcus pneumoniae | 1997 |
Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase.
Topics: Anti-Bacterial Agents; Azithromycin; Cefuroxime; Drug Administration Schedule; Drug Resistance, Microbial; Fluoroquinolones; Haemophilus influenzae; Kinetics; Microbial Sensitivity Tests; Penicillin G; Quinolones; Streptococcus pyogenes | 1997 |
Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antitubercular Agents; Azithromycin; Cell Death; Cell Line; Drug Interactions; Drug Resistance, Microbial; Fluoroquinolones; Humans; Hydrogen Peroxide; Interferon-gamma; Listeria monocytogenes; Listeriosis; Macrophage Activation; Macrophages; Male; Nitric Oxide | 1999 |
Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Azithromycin; Cefaclor; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Erythromycin; Fluoroquinolones; Humans; Models, Economic; Outpatients; Pneumonia; Treatment Outcome | 2000 |
[Comparative in vitro activities of several antimicrobial agents against Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gastric Mucosa; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Penicillins; Stomach Ulcer | 2002 |